HIV Mutations
- HIV Drug Resistance Database (Regularly Updated)
From Stanford University
- HIV Resistance Response Database Initiative (Regularly Updated)
An international nonprofit database of HIV drug mutations.
- National Cancer Institute HIV Drug Resistance Program (Regularly Updated)
This program organizes and conducts research and symposia on HIV drug resistance.
- What Exactly Is a Mutation? And What Are All Those Numbers About? (December 2009)
Part of A Guide to HIV Drug Resistance.
To read PDF, click here.
In A Guide to HIV Drug Resistance, from The Body
- HIV Mutations (December 2009)
Part of A Guide to HIV Drug Resistance.
To read PDF, click here.
In A Guide to HIV Drug Resistance, from The Body
- Researchers Plan to Target Immune Cells Responsible for Eluding Antiretroviral Treatment (May 29, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- New List of HIV Mutations Vital to Tracking AIDS Epidemic (March 11, 2009)
From Stanford University
- HIV's Mutations to Avoid Immune Defenses Can Be Passed to Wider Population, Study Says (February 26, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- HIV Drug Resistance Mutations by Drug Class (PDF) (February 20, 2009)
From Stanford University
- Resistance Analysis of Lopinavir/Ritonavir Maintenance Therapy Study (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Phenotypic Clinical Cutoffs for Tipranavir/Ritonavir Defined Based on RESIST Data (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- How the HIV-1 Reverse Transcriptase Mutations K65R, M184V and K65R + M184V Produce Resistance to NRTIs (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Rise in NRTI Mutations Is Associated With Rise in NNRTI, Protease Inhibitor Mutations (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Sustained Virological Response Still Seen in Treatment-Experienced Patients With K65R and Other Resistance Mutations (August 17, 2006)
In XVI International AIDS Conference
- Emtricitabine and Lamivudine May Be Similar, but Their Resistance Profiles Differ in Important Ways (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- Rare Case of Protease Inhibitor Resistance After Failure of First-Line Boosted Fosamprenavir (December 17, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Researchers Uncover Possible Alternative Pathway to Tenofovir Resistance (December 17, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Analyzing the Pattern of Resistance Mutation Emergence of a Failing Abacavir + Lamivudine + Tenofovir Regimen Reveals a Possible Compensatory Mutation (December 17, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- No K65R Mutations in Patients Failing Tenofovir + Emtricitabine (July 26, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Update of the Drug Resistance Mutations in HIV-1: 2005 (PDF) (March/April 2005)
[Archived Article]
From International AIDS Society Drug Resistance Mutations Group
- K65R Mutation Revealed in 4 Non-Responders to Abacavir + Lamivudine + Tenofovir Failed Regimen -- Significance Unclear (February 25, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Sequencing and 2 of the Most Popular Backbone Regimens (February 25, 2005)
[Archived Article]
A comparison of resistance mutations with abacavir + lamivudine versus tenofovir + lamivudine.
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Is 80%-90% Adherence the Best Predictor of Drug Failure? (February/March 2005)
[Archived Article]
A study suggests that resistance risk is highest for people who have good, but not great, treatment adherence.
From The Body PRO
- Stable Viral Load but Evolving Drug Resistance (January 2005)
[Archived Article]
Part of HIV JournalView's Top 10 Research Reports of 2004.
From The Body PRO
- The Risk of NNRTI Resistance Following Perinatal Nevirapine and Ramifications for Subsequent Antiretroviral Therapy Success (January 2005)
[Archived Article]
Part of HIV JournalView's Top 10 Research Reports of 2004.
From The Body PRO
- Single-Dose Drugs May Be Effective, But They Can Jeopardize Long-Term Therapy (November/December 2004)
[Archived Article]
Recent studies bring potentially bad news for HIV drugs with long half-lives.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- HIV JournalView: Prevalence, Incidence and Predictors of K65R (October 2004)
[Archived Article]
From The Body PRO
- Viral Load Between 400 and 20,000 Can Still Maintain Patient Health (September 7, 2004)
[Archived Article]
Partially suppressive HAART appears to protect against death and illness as well as fully suppressive HAART.
From aidsmap.com
- HIV JournalView: Primary Drug Resistance Can Persist a Year or More (September 2004)
[Archived Article]
From The Body PRO
- HIV JournalView: Stable Viral Load but Evolving Drug Resistance (August 2004)
[Archived Article]
Analysis of a study published in the journal AIDS.
From The Body PRO
- NNRTI Resistance Occurs More Often at Lower Levels of Adherence Than Does PI Resistance (July 14, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- Intermittent Drug Switching Can Resensitize Patients With Multidrug-Resistant HIV-1 (July 13, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- NNRTI Not Working? It May Be Safe to Stop It, One Study Suggests (June 28, 2004)
[Archived Article]
If a patient has become resistant to the NNRTI in a HAART combination, cutting the NNRTI out of the regimen appears to do no additional harm.
From aidsmap.com
- Drug Resistance in Treatment-Naive Patients Only Briefly Impacts CD4 Counts (June 22, 2004)
[Archived Article]
From aidsmap.com
- Genotyping, Web-Based Program Select Rescue Regimens for HIV-Infected Children (June 15, 2004)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Emergence of Resistance-Associated Mutations Over 96 Weeks in Patients Initiating ABC/3TC + d4T, EFV or APV/r (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- NNRTI Resistance Can Occur in the Absence of Known Mutations (September 14, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Resistance Still Possible Despite Perfect Adherence, Study Says (August 28, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Treatment Interruption Shows No Benefit in Drug-Resistant HIV Infection (August 27, 2003)
[Archived Article]
From U.S. National Institute of Allergy and Infectious Diseases
- Japan: Doctors Say Drug-Resistant HIV on Rise (August 7, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Low-Level Resistance and Minority Populations: Cross-Resistance Between Nevirapine and Efavirenz (August/September 2003)
[Archived Article]
Once an NNRTI-based regimen fails, no other NNRTIs will work any better, two studies suggest.
In Treatment Bulletin, from HIV i-Base
- Drug-Resistant HIV Strains Found in One Out of Every 10 Newly Infected European Patients (July 16, 2003)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Is Trizivir Plus Tenofovir Effective in Patients With Possible or Proven Reverse Transcriptase Resistance? (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Decreased Replication Capacity of HIV-1 Clinical Isolates Containing K65R or M184V RT Mutations (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Baseline and On-Treatment Susceptibility to Enfuvirtide Seen in TORO 1 and TORO 2 to 24 Weeks (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Effect of Amprenavir Hypersusceptibility on the Response to APV/Ritonavir-Based Therapy in ART-Experienced Adults Selected by Baseline Susceptibility (ESS40006): 24-Week Data (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Prevalence of Mutations Associated With Resistance to Antiretroviral Therapy From 1999-2002 (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- NEFA Simplification Trial: Genotypic and Phenotypic Resistance Patterns Among Patients With Virological Failure (February 11, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Comparative Incidence and Temporal Accumulation of PI and NRTI Resistance in HIV-Infected Subjects Receiving Lopinavir/Ritonavir or Nelfinavir as Initial Therapy (February 11, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Antiretroviral Resistance Among Patients With Primary HIV Infection in the Southeastern U.S. -- Impact on Treatment Outcome (February 11, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Baseline Phenotypic Susceptibility to Tipranavir/Ritonavir Is Retained in Isolates From Patients With Multiple Protease Inhibitor Experience (February 11, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Viral Adaptation to Nelfinavir (January/February 2003)
[Archived Article]
The first reported evidence of drug-dependent enhancement of HIV replication.
In TAGline, from Treatment Action Group
- Cell Cycles, HIV Drugs and Treatment (January 2003)
[Archived Article]
Research from the 2002 International AIDS Conference.
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- The Development of K65R Versus Thymidine Analogue-Associated Mutations in Antiviral-Treated Patients (November 21, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Shift in HIV-1 Resistance After Treatment Interruption in Patients With Virological Failure and Antiviral Effect Following Trizivir Plus Efavirenz (AZLF3003 Study) (November 19, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Data From the 14th International AIDS Conference: Resistance Challenge (October 2002)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Expert Opinion From Barcelona: Resistance: What Have We Learned? (September/October 2002)
[Archived Article]
In Positively Aware, from Test Positive Aware Network
- Drug Resistance and the Treatment of Experienced Patients (September 2002)
[Archived Article]
A report from the International AIDS Conference.
In Hopkins HIV Report
- HIV Resistance Meeting Highlights (Fall 2002)
[Archived Article]
In STEP Perspective, from Seattle Treatment Education Project
- Digging Deeper at the Resistance Workshop (August 14, 2002)
[Archived Article]
Key clinical findings from July's XI International HIV Drug Resistance Workshop.
From International AIDS Society
- Antiretroviral-Drug Resistance Among Patients Recently Infected With HIV (August 8, 2002)
[Archived Article]
Greater primary resistance necessitates earlier drug-resistance testing, researchers say.
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected Persons (July 29, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Strategies to Prevent Loss of CD4+ and Onset of Resistance During Treatment Interruptions (July 11, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Genotypic and Virtual Phenotypic Correlates of Virologic Response to Abacavir-Based Therapy in the ZORRO Trial (ESS40009) (July 11, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Prevalence of Genotypic Drug Resistance in HIV-Infected Individuals in New York State: The Resistance Study (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Resistance Profiles at Baseline and Following Virologic Failure for Subjects Randomized to Receive Abacavir/Efavirenz/Didanosine +/-; Hydroxyurea After Failing Initial NRTI +/- PI Therapy (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Phenotypic and Genotypic Profiles Predict Week 24 Responses to an Abacavir-Containing Salvage Regimen (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- High Incidence of Primary NNRTI Mutations and M184V in Isolates From Therapy-Experienced Adults Entering the ZORRO Trial (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- HIV Drug Resistance Mutations (PDF) (May/June 2002)
[Archived Article]
Updated figures representing the latest in antiretroviral resistance research.
From International AIDS Society
- The Buzz: The Disconnect Syndrome -- A Controversial Dilemma (May/June 2002)
[Archived Article]
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Studies of PI-Resistant Virus Offer Tantalizing Possibilities for Immune Reconstitution (May 2002)
[Archived Article]
"The 1,500 copy cut-off".
In TAGline, from Treatment Action Group
- Treatment of Patients With Drug-Resistant Virus (February 27, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- New Insights Into Mechanisms of HIV-1 Resistance to Reverse Transcriptase Inhibitors (February 27, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Molecular Mechanism of I50V, I54L and I54M Resistance to Amprenavir and Other HIV-1 Protease Inhibitors (February 26, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The Genetic Edge: Fighting Drug Resistance in a Protein's Genes (January 2002)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
- P-Glycoprotein and HIV (January 2002)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
- HIV Resistance: Data and Spin (December 28, 2001)
[Archived Article]
To read PDF, click here.
In AIDS Treatment News, from AIDS Treatment News
- Variations in HIV-1 Gag p6 Contribute to the Amprenavir-Specific Protease I50V Resistance Pathway (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Diverse Effects of NRTI-Associated Mutations on Resistance to Abacavir, Stavudine and Zidovudine in the ZORRO Trial (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Impact of M184V/I Mutation on HIV Phenotypic Resistance to Nucleoside Analogs in NRTI-Experienced Patients (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- The Prevalence of Antiretroviral Drug Resistance in the U.S. (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Impact on Fitness Conferred by Amprenavir Resistance Mutations (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors and Antiretroviral History Do Not Affect Virologic Response to T-1249 (December 17, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Comparison of Nevirapine Resistance Mutations in Women vs. Infants Receiving Single Dose NVP Prophylaxis to Prevent HIV-1 Vertical Transmission (HIVNET 012) (December 16, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- New Zidovudine-Resistant HIV Found in Treatment-Naive Patients (December 2001)
[Archived Article]
In HEPP News, from Brown Medical School
- Viral Load: Small Change by Sixth Day of Treatment Can Often Predict Poor Response (November 23, 2001)
[Archived Article]
To read PDF, click here.
In AIDS Treatment News, from AIDS Treatment News
- New Finding May Help Doctors Prevent HIV Drug Resistance (November 22, 2001)
[Archived Article]
From U.S. National Institute of Allergy and Infectious Diseases
- Viral "Blips" May Not Indicate Treatment Failure (November 2001)
[Archived Article]
In OUTReach, from San Francisco AIDS Foundation
- Predicting the Unpredictable: The Transmission of Drug-Resistant HIV (October 27, 2001)
[Archived Article]
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Relationship Between Prior Antiretroviral Therapy and Genotypic Testing Among a Large Cohort of HIV-1 Isolates (October 27, 2001)
[Archived Article]
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Researchers Predict That 42 Percent of HIV in San Francisco Will Be Drug-Resistant by 2005 (September 4, 2001)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Resistance Testing: A Look at the Data (Fall 2001)
[Archived Article]
To read PDF, click here.
In CRIA Update, from AIDS Community Research Initiative of America
- HIV Resistance Meeting Web Reports (July 13, 2001)
[Archived Article]
To read PDF, click here.
In AIDS Treatment News, from AIDS Treatment News
- Prevalence of Phenotypic Resistance to Amprenavir in Protease-Inhibitor-Experienced Patients: Data from CNAB3008 (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Comparison of Drug Susceptibility in HIV-1 From Antiretroviral-Experienced Subjects as Assessed by the Antivirogram and PhenoSense Assays (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Genetic Correlates of Phenotypic Hypersusceptibility to Efavirenz (EFV) in Highly Nucleoside-Experienced Subjects in ACTG 364 (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- New Antiretrovirals Host Immunology, Pathogenesis and Dynamics Mechanisms of HIV-Drug Resistance Drug Resistance, Exposure and Treatment Response Genotype/Phenotype Relationship, Modelling and Algorithms (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Primary Genotypic and Phenotypic HIV-1 Drug Resistance in Recent Seroconverters in Madrid (July 2001)
[Archived Article]
In Body Positive, from Body Positive
- Is Transmitted Drug Resistance in HIV on the Rise? It Seems So (May 5, 2001)
[Archived Article]
In British Medical Journal
- Antiretroviral Resistance Mutations (April 2001)
[Archived Article]
A collaborative effort of the International AIDS Society-USA Resistance Testing Panel and HIV InSite.
- HIV Drug Resistance and Drug-Resistance Testing (March 2001)
[Archived Article]
To read PDF, click here.
In The PRN Notebook
- A Controlled Phase II Trial Assessing Three Doses of T-20 in Combination With Abacavir, Amprenavir, Low-Dose Ritonavir and Efavirenz in Non-Nucleoside-Naive Protease-Inhibitor-Experienced HIV-1 Infected Adults (February 8, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Antiretroviral Intensification Accelerates the Decay of the Latent Reservoir of HIV-1 and Decreases but Does Not Eliminate Ongoing Virus Replication (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Virologic Suppression From Different Thymidine Analogue-Containing HAART Regimen Sequencing Strategies: VIRA 3001 (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Viral Resistance Results From the International, Multicenter, Randomized, Placebo-Controlled, 48-Week Study of Hydroxyurea or Placebo Combined With Efavirenz, Didanosine and Stavudine in Treatment-Naive and -Experienced Patients (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Plasma Trough Levels Correlate with Distinct Genetic Mechanisms During the Development of Amprenavir Resistance (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Phenotypic Susceptibility and Virologic Responses in Nucleoside Reverse Transcriptase Inhibitor-Experienced Subjects Receiving NRTIs + Efavirenz (EFV), Nelfinavir (NFV), or Both in ACTG 364 (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Time to Appearance of NRTI-Associated Mutations and Response to Subsequent Therapy for Patients on Failing ABC/COM (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- A Prospective, Randomized Study on the Usefulness of Genotypic Resistance Testing and the Assessment of Patient-Reported Adherence in Unselected Patients Failing Potent HIV Therapy (ARGENTA): Final 6-Month Results (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Prevalence of Drug-Resistant HIV-1 Variants in Newly Infected Individuals During 1999-2000 (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Genotypic Resistance at Baseline Fails to Predict Outcome Among Chronically Infected, Antiretroviral-Therapy-Naive Patients in Two Large Trials of PI-Based Regimens (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Determination of a Clinically Relevant Phenotypic Resistance "Cutoff" for Abacavir Using the PhenoSense Assay (February 5, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- DPC 681 and DPC 684: Resistance and Cross-Resistance Profiles of Second Generation HIV Protease Inhibitors (February 5, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Case Management: Michael T., a Longterm Survivor Who Is Failing His Fifth Salvage Regimen (February 2001)
[Archived Article]
In HIV Newsline, from San Francisco General Hospital
- Superinfection (Reinfection): New Study in San Francisco Offers Free Resistance and Viral Load Testing (December 1, 2000)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- Novel Aspects of Resistance to Antiretroviral Agents (September 2000)
[Archived Article]
In The 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Report From the 4th International Workshop on HIV Drug Resistance and Treatment Strategies (September 2000)
[Archived Article]
In Research Initiative/Treatment Action!, from The Center for AIDS
- AZT and d4T Cross-Resistance (August 8, 2000)
[Archived Article]
In STEP Ezine, from Seattle Treatment Education Project
- Using Resistance Data to Make Treatment Decisions (August 8, 2000)
[Archived Article]
In STEP Ezine, from Seattle Treatment Education Project
- The Atlantic Study: A Randomized, Open-Label Trial Comparing Two Protease Inhibitor-Sparing Antiretroviral Strategies Versus a Standard PI-Containing Regimen, Final 48-Week Data (July 13, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- Phenotypic Resistance Testing Significantly Improves Response to Therapy: A Randomized Trial (VIRA3001) (July 13, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- Two Studies Shed Light on Development of d4T Resistance (July 13, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- Epidemiologic Surveillance of HIV Resistance From 1994 to 1999; Increasing Frequency of Naive Patient Mutants (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- Transmission of Drug-Resistant HIV-1 in San Francisco (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- Research Updates on DPC 083, DPC 961 and DAPD (July 11, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- Low Frequency of Genotypic Resistance Markers in Therapy-Naive HIV+ Adolescents (July 11, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- Symposium: Management of Drug Resistance (July 10, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- 4th International Workshop on HIV Drug Resistance and Treatment Strategies (June 12 - 16, 2000)
In The 4th International Workshop on HIV Drug Resistance and Treatment Strategies, from The Body PRO
- Prevalence of Drug Resistance High (June 16, 2000)
[Archived Article]
From Canadian AIDS Treatment Information Exchange
- Selection of Antiretroviral Resistance in the Latent Reservoir of Human Immunodeficiency Virus Type 1 During Successful Therapy (January 31, 2000)
[Archived Article]
In The 7th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Phenotypic Resistance Testing Significantly Improves Response to Therapy: A Randomized Trial (VIRA 3001) (January 31, 2000)
[Archived Article]
From Seattle Treatment Education Project
- Reduced Susceptibility to NRTI Is Associated With NNRTI Hypersensitivity in Virus From HIV-1-Infected Patients (January 31, 2000)
[Archived Article]
From Seattle Treatment Education Project
- Measuring the Replicative Fitness of Recombinant HIV-1 Vectors Expressing Protease and Reverse Transcriptase Derived From Patient Viruses (January 31, 2000)
[Archived Article]
From Seattle Treatment Education Project
- Multdrug-Resistant HIV and Primary Infection: A New Threat to At-Risk Individuals, and a New Challenge for Care Providers (October 1999)
[Archived Article]
In HIV Newsline, from San Francisco General Hospital
- Drug-Specific Resistance (Summer 1999)
[Archived Article]
In Women Alive Newsletter, from Women Alive
- Chemokines and HIV Coreceptors: Opening Doors to New Anti-HIV Strategies (May 25, 1999)
[Archived Article]
From U.S. National Institute of Allergy and Infectious Diseases
- Drug Failure and Other Pleasant Surprises (Spring 1999)
[Archived Article]
In Notes From the Underground, from PWA Health Group
- Selection of Protease Resistance Mutations in Semen (February 4, 1999)
[Archived Article]
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The Spectrum and Frequency of Reduced Antiretroviral Drug Susceptibility With Primary HIV Infection in the United States (February 4, 1999)
[Archived Article]
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- High Frequency of Antiretroviral Drug Resistance in HIV-1 From Recently Infected Therapy Naive Individuals (February 4, 1999)
[Archived Article]
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The Multiple Nucleoside Analogue Resistance Mutations Confer Cross-Resistance to Abacavir (February 1, 1999)
[Archived Article]
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Mutations in the Reverse Transcriptase Genome of HIV I Isolates Derived from Subjects Treated with Didanosine and Stavudine in Combination (February 1, 1999)
[Archived Article]
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Reverse Transcriptase Genotype After Multiple, Sequential Nucleoside Analog Drugs and Their Response to HAART and ACTG 364 (February 1, 1999)
[Archived Article]
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
|
Advertisement
|
Email
Glossary
